Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: The prophylactic acetazolamide dosage comparison for efficacy (PACE) trial

High Altitude Medicine and Biology

Volumn 7, Issue 1, 2006, Pages 17-27

  Basnyat, Buddha ^a   Gertsch, Jeffrey H ^a   Holck, Peter S ^a   Johnson, E William ^a   Luks, Andrew M ^a   Donham, Benjamin P ^a   Fleischman, Ross J ^a   Gowder, Daniel W ^a   Hawksworth, Jason S ^a   Jensen, Brett T ^a   Kleiman, Richard J ^a   Loveridge, Adam H ^a   Lundeen, Elizabeth B ^a   Newman, Sheri L ^a   Noboa, Jesse A ^a   Miegs, Daniel P ^a   O'Beirne, Kenneth A ^a   Philpot, Kelly B ^a   Schultz, Miriam N ^a   Valente, Matthew C ^a   Wiebers, Mandie R ^a   Swenson, Erik R ^a   more..

^a NEPAL INTERNATIONAL CLINIC   (Nepal)

Author keywords

Acetazolamide dose comparison; Altitude sickness; Drug prophylaxis; Nepal; Prevention; Trekking

Indexed keywords

ACETAZOLAMIDE; OXYGEN; PLACEBO;

ADULT; ALTITUDE DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DYSGEUSIA; FEMALE; HUMAN; INCIDENCE; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MOUNTAINEERING; NEPAL; OXYGEN SATURATION; OXYGENATION; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACETAZOLAMIDE; ADULT; ALTITUDE; ALTITUDE SICKNESS; CARBONIC ANHYDRASE INHIBITORS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOUNTAINEERING; NEPAL; ODDS RATIO; PROSPECTIVE STUDIES; PULMONARY EDEMA; TREATMENT OUTCOME;

EID: 33645651531     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2006.7.17     Document Type: Article

References (23)

1. Bartsch P., Bailey D.M., Berger M.M., Knauth M., and Baumgartner R.W. (2004). Acute mountain sickness: controversies and advances. High Alt. Med. Biol. 5:110-124.
2. Bartsch P., and Schneider M. (2001). Same ascent rates must be used to assess effectiveness of different doses of acetazolamide. BMJ 392:48.
3. Basnyat B., Gertsch J.H., Johnson E.W., Castro Marin F., Inoue Y., and Yeh C. (2003). Efficacy of low dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness. High Alt. Med. Biol. 4:45-52.
4. Basnyat B., Lemaster J., and Litch J.A. (1999). Everest or bust: a cross sectional, epidemiological survey of acute mountain sickness at 4234 rn in the Himalayas. Aviat. Space Environ. Med. 70:867-873.
5. Basnyat B., and Murdoch D.R. (2003). High altitude illness. Lancet 361:1967-1974.
6. Berthelsen P., Gothgen I., Husum B., and Jacobsen E. (1986). Dissociation of renal and respiratory effects of acetazolamide in the critically ill. Br. J. Anaesth. 58:512-516.
7. Carlsten C., Swenson E.R., and Ruoss S. (2004). A dose response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630m). High Alt. Med. Biol. 5:33-39.
8. Collier D., Nathan J., Flower R., Swenson E.R., and Milledge J.S. (1996). Benzolamide, a selective renal carbonic anhydrase inhibitor, prevents acute mountain sickness in man. J. Physiol. 523:A245.6.
9. Dumont L., Mardirosoff C., and Tramer M. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitive systematic review. BMJ 321:267-272.
10. Gertsch J.H., Basnyat B., Johnson W.E., Onopa J., and Holck P.S. (2004). On behalf of the prevention of High Altitude Illness Trial Research Group. Randomised, controlled trial of Ginko Biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT). BMJ 328:797-799.
11. Hackett P.H., Rennie D., and Levine H.D. (1976). The incidence, importance, and prophylaxis of acute mountian sickness. Lancet 2:1149-1154.
12. Hackett P.H., and Roach R.C. (2001). High altitude illness. N. Engl. J. Med. 345:107-114.
13. Hardman J.G., Limbird L.E., Gilman A.G., eds. (2001). Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill.
14. Leadbetter G.W., Hackett P.H., Maakestad K., Tissot van Patot M., Olson S., Keyes L., Sheets A., and Roach R. (2003). Comparison of Ginko Biloba, acetazolamide, and placebo for prevention of acute mountain sickness. Abstracts from the 13th International Hypoxia Symposium, Banff, Canada, February 19-22, 2003. High Alt. Med. Biol. 3:455.
15. Murdoch D.R. (1995). Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat. Space Environ. Med. 66:148-151.
16. Ried L.D., Carter K.A., and Ellsworth A. (1994). Acetazolamide or dexamethazone for prevention of acute mountain sickness: a meta-analysis. J. Wilderness Med. 5:34-48.
17. Ritschel W.A., Paulos C., Arancibia A., Agrawal M.A., Wetzelsberger K.M., and Lucker P.W. (1998). Pharmacokinetics of acetazolamide in healthy volunteers after short and long-term exposure to high altitude. J. Clin. Pharmacol. 38:533-539.
18. Roach R.C., Bartsch P., Hackett P.H., and Oelz O. The Lake Louise AMS Scoring Consensus Committee (1993). The Lake Louise acute mountain sickness scoring system. In: J.R. Sutton, G. Coates, and C.S. Houston, eds. (1993 Feb. 9-13). Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium, Lake Louise, Alberta, Canada, 272-1274.
19. Schneider M., Bernasch D., Weymann J., Holle R., and Bartsch P. (2002). Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med. Sci. Sports Exp. 1886-1891.
20. Severinghaus J.W. (2001). Sightings: diamox debate. High Alt. Med. Biol. 2:9.
21. Swenson E.R. (1998). Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression. Eur. Respir. J. 12:1242-1247.
22. Swenson E.R., Leatham K.L., Roach R.C., Schoene R.B., Mills W.J. Jr., and Hackett P.H. (1991). Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing. Respir. Physiol. 86:333-343.
23. Swenson E.R., Maggiorini M., Mongovin S., Gibbs J.S., Geve I., Mairbaurl H., and Bartsch P. (2002). Pathogenesis of high altitude pulmonary edema: inflammation is not an etiologic factor. JAMA 287:9228-9235.